Relative reductions in soluble CD30 levels post-transplant predict acute graft function in islet allograft recipients receiving three different immunosuppression protocols

Transplant Immunology

Volumn 23, Issue 4, 2010, Pages 209-214

  Hire, Kelly ^a   Hering, Bernhard ^a   Bansal Pakala, Pratima ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Islet allograft; SCD30; Transplantation tolerance

Indexed keywords

CD30 ANTIGEN; CYCLOSPORIN; DACLIZUMAB; ETANERCEPT; EVEROLIMUS; INSULIN; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOGRAFT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FUNCTIONAL ASSESSMENT; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS DISEASE; PANCREAS FUNCTION; PANCREAS ISLET TRANSPLANTATION; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ANTIGENS, CD30; ANTILYMPHOCYTE SERUM; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; ISLETS OF LANGERHANS TRANSPLANTATION; PROGNOSIS; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 77956060537     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2010.06.007     Document Type: Article

References (36)

1. Schlaf G., Altermann W.W., Rothhoff A., Seliger B. Soluble CD30 serum level - an adequate marker for allograft rejection of solid organs?. Histol Histopathol 2007, 22:1269-1279.
2. Caligaris-Cappio F., Bertero M.T., Converso M., Stacchini A., Vinante F., Romagnani S., et al. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 1995, 13:339-343.
3. Makhseed M., Raghupathy R., Azizieh F., Farhat R., Hassan N., Bandar A. Circulating cytokines and CD30 in normal human pregnancy and recurrent spontaneous abortions. Hum Reprod 2000, 15:2011-2017.
4. Pizzolo G., Vinante F., Nadali G., Krampera M., Morosato L., Chilosi M., et al. High serum level of soluble CD30 in acute primary HIV-1 infection. Clin Exp Immunol 1997, 108:251-253.
5. Fattovich G., Vinante F., Giustina G., Morosato L., Alberti A., Ruol A., et al. Serum levels of soluble CD30 in chronic hepatitis B virus infection. Clin Exp Immunol 1996, 103:105-110.
6. Leonard C., Tormey V., Faul J., Burke C.M., Poulter L.W. Allergen-induced CD30 expression on T cells of atopic asthmatics. Clin Exp Allergy 1997, 27:780-786.
7. Cinti P., Pretagostini R., Arpino A., Tamburro M.L., Mengasini S., Lattanzi R., et al. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations. Transplantation 2005, 79:1154-1156.
8. Heinemann F.M., Rebmann V., Witzke O., Philipp T., Broelsch C.E., Grosse-Wilde H. Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation. Transplantation 2007, 83:706-711.
9. Langan L.L., Park L.P., Hughes T.L., Irish A., Luxton G., Witt C.S., et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007, 7:847-856.
10. Sengul S., Keven K., Gormez U., Kutlay S., Erturk S., Erbay B. Identification of patients at risk of acute rejection by pretransplantation and posttransplantation monitoring of soluble CD30 levels in kidney transplantation. Transplantation 2006, 81:1216-1219.
11. Susal C., Pelzl S., Dohler B., Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002, 13:1650-1656.
12. Susal C., Pelzl S., Simon T., Opelz G. Advances in pre- and posttransplant immunologic testing in kidney transplantation. Transplant Proc 2004, 36:29-34.
13. Wang D., Wu G.J., Wu W.Z., Yang S., Chen J., Wang H., et al. Pre- and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection. Transpl Immunol 2007, 17:278-282.
14. Yang J.L., Hao H.J., Zhang B., Liu Y.X., Chen S., Na Y.Q. Level of soluble CD30 after kidney transplantation correlates with acute rejection episodes. Transplant Proc 2008, 40:3381-3383.
15. Susal C., Pelzl S., Opelz G. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation 2003, 76:1231-1232.
16. Vaidya S., Partlow D., Barnes T., Gugliuzza K. Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies. Transplantation 2006, 82:1606-1609.
17. Shah A.S., Leffell M.S., Lucas D., Zachary A.A. Elevated pretransplantation soluble CD30 is associated with decreased early allograft function after human lung transplantation. Hum Immunol 2009, 70:101-103.
18. Truong D.Q., Darwish A.A., Gras J., Wieers G., Cornet A., Robert A., et al. Immunological monitoring after organ transplantation: potential role of soluble CD30 blood level measurement. Transpl Immunol 2007, 17:283-287.
19. Cervelli C., Fontecchio G., Scimitarra M., Azzarone R., Famulari A., Pisani F., et al. Evaluation of serum sCD30 in renal transplantation patients with and without acute rejection. Transplant Proc 2009, 41:1159-1161.
20. Dong W., Shunliang Y., Weizhen W., Qinghua W., Zhangxin Z., Jianming T., et al. Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30. Transpl Immunol 2006, 16:41-45.
21. Giannoli C., Bonnet M.C., Perrat G., Houillon A., Reydet S., Pouteil-Noble C., et al. High pretransplantation soluble CD30 levels: impact in renal transplantation. Transplant Proc 2007, 39:2574-2575.
22. Kim M.S., Kim H.J., Kim S.I., Ahn H.J., Ju M.K., Kim H.J., et al. Pretransplant soluble CD30 level has limited effect on acute rejection, but affects graft function in living donor kidney transplantation. Transplantation 2006, 82:1602-1605.
23. Kovac J., Arnol M., Vidan-Jeras B., Bren A.F., Kandus A. Does pretransplant soluble CD30 serum concentration affect deceased-donor kidney graft function 3years after transplantation?. Transplant Proc 2008, 40:1357-1361.
24. Nafar M., Farrokhi F., Vaezi M., Entezari A., Pour-Reza-Gholi F., Firoozan A., et al. Pre-transplant and post-transplant soluble CD30 for prediction and diagnosis of acute kidney allograft rejection. Int Urol Nephrol 2009, 41:687-693.
25. Platt R.E., Wu K.S., Poole K., Newstead C.G., Clark B. Soluble CD30 as a prognostic factor for outcome following renal transplantation. J Clin Pathol 2009, 62:662-663.
26. Slavcev A., Honsova E., Lodererova A., Pavlova Y., Sajdlova H., Vitko S., et al. Soluble CD30 in patients with antibody-mediated rejection of the kidney allograft. Transpl Immunol 2007, 18:22-27.
27. Matinlauri I., Hockerstedt K., Isoniemi H. High serum soluble CD30 does not predict acute rejection in liver transplant patients. Transplant Proc 2006, 38:3601-3604.
28. Spiridon C., Hunt J., Mack M., Rosenthal J., Anderson A., Eichhorn E., et al. Evaluation of soluble CD30 as an immunologic marker in heart transplant recipients. Transplant Proc 2006, 38:3689-3691.
29. Spiridon C., Nikaein A., Lerman M., Hunt J., Dickerman R., Mack M. CD30, a marker to detect the high-risk kidney transplant recipients. Clin Transpl 2008, 22:765-769.
30. Bellin M.D., Kandaswamy R., Parkey J., Zhang H.J., Liu B., Ihm S.H., et al. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant 2008, 8:2463-2470.
31. Hering B.J., Kandaswamy R., Ansite J.D., Eckman P.M., Nakano M., Sawada T., et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005, 293:830-835.
32. Hering B.J., Kandaswamy R., Harmon J.V., Ansite J.D., Clemmings S.M., Sakai T., et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004, 4:390-401.
33. Campbell P.M., Senior P.A., Salam A., Labranche K., Bigam D.L., Kneteman N.M., et al. High risk of sensitization after failed islet transplantation. Am J Transplant 2007, 7:2311-2317.
34. Saini D., Ramachandran S., Nataraju A., Benshoff N., Liu W., Desai N., et al. Activated effector and memory T cells contribute to circulating sCD30: potential marker for islet allograft rejection. Am J Transplant 2008, 8:1798--1808.
35. Pelzl S., Opelz G., Daniel V., Wiesel M., Susal C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003, 75:421-423.
36. Altermann W., Schlaf G., Rothhoff A., Seliger B. High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection?. Nephrol Dial Transplant 2007, 22:2795-2799.